WO2005018539A8 - Influenza hemagglutinin and neuraminidase variants - Google Patents

Influenza hemagglutinin and neuraminidase variants Download PDF

Info

Publication number
WO2005018539A8
WO2005018539A8 PCT/US2004/019372 US2004019372W WO2005018539A8 WO 2005018539 A8 WO2005018539 A8 WO 2005018539A8 US 2004019372 W US2004019372 W US 2004019372W WO 2005018539 A8 WO2005018539 A8 WO 2005018539A8
Authority
WO
WIPO (PCT)
Prior art keywords
influenza hemagglutinin
neuraminidase variants
neuraminidase
variants
hemagglutinin
Prior art date
Application number
PCT/US2004/019372
Other languages
French (fr)
Other versions
WO2005018539A2 (en
Inventor
Chin-Fen Yang
George Kemble
C. G. Liu
Original Assignee
Medimmune Vaccines, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Vaccines, Inc. filed Critical Medimmune Vaccines, Inc.
Priority to EP04785947A priority Critical patent/EP1633312A4/en
Priority to CA2529647A priority patent/CA2529647C/en
Publication of WO2005018539A2 publication Critical patent/WO2005018539A2/en
Publication of WO2005018539A8 publication Critical patent/WO2005018539A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation
PCT/US2004/019372 2003-06-16 2004-06-16 Influenza hemagglutinin and neuraminidase variants WO2005018539A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04785947A EP1633312A4 (en) 2003-06-16 2004-06-16 Influenza hemagglutinin and neuraminidase variants
CA2529647A CA2529647C (en) 2003-06-16 2004-06-16 Influenza hemagglutinin and neuraminidase variants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47907803P 2003-06-16 2003-06-16
US60/479,078 2003-06-16

Publications (2)

Publication Number Publication Date
WO2005018539A2 WO2005018539A2 (en) 2005-03-03
WO2005018539A8 true WO2005018539A8 (en) 2012-05-31

Family

ID=34215806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/019372 WO2005018539A2 (en) 2003-06-16 2004-06-16 Influenza hemagglutinin and neuraminidase variants

Country Status (4)

Country Link
US (8) US7566458B2 (en)
EP (2) EP2581093B1 (en)
CA (2) CA2816222A1 (en)
WO (1) WO2005018539A2 (en)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2252261T3 (en) * 2000-06-28 2006-05-16 Glycofi, Inc. METHODS TO PRODUCE MODIFIED GLICOPROTEINS.
CN103540568A (en) * 2002-04-26 2014-01-29 米迪缪尼有限公司 Multi plasmid system for the production of influenza virus
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
EP1664322B1 (en) 2003-05-22 2013-07-10 Fraunhofer USA, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
AU2004308328B2 (en) 2003-12-23 2009-06-04 Medimmune, Llc Multi plasmid system for the production of influenza virus
JP4980896B2 (en) * 2004-05-25 2012-07-18 メディミューン，エルエルシー Influenza hemagglutinin and neuraminidase variants
ES2531734T3 (en) 2004-10-06 2015-03-18 Medimmune, Llc Flu vaccine compositions stable at refrigerator temperatures
EP2441471B1 (en) * 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
JP2009502207A (en) 2005-08-03 2009-01-29 フラウンホーファー ユーエスエー， インコーポレイテッド Compositions and methods for the production of immunoglobulins
AU2006309007A1 (en) * 2005-10-28 2007-05-10 Boehringer Ingelheim Vetmedica, Inc Use of vaccines for the treatment/ prevention of the transmission of influenza pathogens between species
CA2628837C (en) * 2005-11-07 2018-11-27 Sidney Kimmel Cancer Center Cd40 ligand fusion protein vaccine
JP2009526526A (en) * 2006-02-13 2009-07-23 フラウンホーファー ユーエスエー， インコーポレイテッド Influenza antigens, vaccine compositions, and related methods
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
WO2007095155A2 (en) * 2006-02-13 2007-08-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Primers and probes for detection and discrimination of types and subtypes of influenza viruses
WO2007095320A2 (en) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Hpv antigens, vaccine compositions, and related methods
US9254318B2 (en) 2006-03-31 2016-02-09 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
US7993655B2 (en) 2006-04-21 2011-08-09 Dow Agrosciences Llc Vaccine for avian influenza and methods of use
CA2659592C (en) 2006-07-14 2016-10-04 Konstantin V. Pugachev Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
EP2049662A4 (en) * 2006-07-21 2009-12-30 Medimmune Llc Methods and compositions for increasing replication capacity of an influenza virus
KR101586971B1 (en) * 2006-08-09 2016-02-22 메디뮨 엘엘씨 Influenza hemagglutinin and neuraminidase variants
AU2013206611B2 (en) * 2006-08-09 2016-01-14 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US20090098527A1 (en) * 2006-09-12 2009-04-16 Fischer Gerald W Biological organism identification product and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8084443B2 (en) 2007-10-01 2011-12-27 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
US20080124355A1 (en) * 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
AU2007347184A1 (en) 2006-09-29 2008-08-21 Sanofi Pasteur Biologics Co Recombinant rhinovirus vectors
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
BRPI0810865A2 (en) * 2007-04-28 2017-05-09 Fraunhofer Usa Inc trypanosome antigens, vaccine compositions, and related methods
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
CN101715487A (en) * 2007-06-18 2010-05-26 米迪缪尼有限公司 influenza b viruses having alterations in the hemaglutinin polypeptide
PL2185191T3 (en) * 2007-06-27 2013-02-28 Novartis Ag Low-additive influenza vaccines
CA2692933C (en) 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
WO2009018500A1 (en) * 2007-07-31 2009-02-05 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
CA2696764A1 (en) * 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
EP3058954B1 (en) * 2007-08-27 2017-03-01 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
EP2238253B1 (en) 2007-11-27 2012-09-12 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
US8709713B2 (en) 2008-03-21 2014-04-29 Mayo Foundation For Medical Education And Research Viruses lacking epithelial cell receptor entry
CN102123724B (en) * 2008-06-19 2018-05-01 变异生技公司 Treat the composition and method of influenza
US8771703B2 (en) * 2008-07-08 2014-07-08 Medicago Inc. Soluble recombinant influenza antigens
WO2010006144A2 (en) * 2008-07-11 2010-01-14 Medlmmune, Llc. Influenza hemagglutinin and neuraminidase variants
MY161965A (en) * 2008-07-18 2017-05-15 Medicago Inc New influenza virus immunizing epitope
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
EA024262B1 (en) * 2008-11-25 2016-09-30 Нанотерапьютикс Инк. METHOD FOR PRODUCTION OF pH STABLE HIGHLY INFECTIOUS INFLUENZA VIRUS
SG172220A1 (en) 2008-12-16 2011-07-28 Baxter Int Production of influenza vaccines
DK2396032T3 (en) 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenza vaccines with reduced amounts of squalene
AU2010213966B2 (en) * 2009-02-12 2015-01-22 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US20120094274A1 (en) * 2009-05-04 2012-04-19 Ibis Biosciences, Inc. Identification of swine-origin influenza a (h1n1) virus
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
AU2010265766B2 (en) 2009-06-24 2015-03-19 Medicago Inc. Chimeric influenza virus-like particles comprising hemagglutinin
JP5551780B2 (en) 2009-09-22 2014-07-16 メディカゴ インコーポレイテッド Method for preparing plant-derived protein
CA2776144C (en) 2009-09-29 2020-10-27 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
WO2011056591A1 (en) 2009-10-26 2011-05-12 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
US20110184160A1 (en) * 2010-01-26 2011-07-28 Weiner David B Nucleic acid molecule encoding consensus influenza a hemagglutinin h1
WO2011108999A1 (en) * 2010-03-05 2011-09-09 Agricultural Research Development Agency (Public Organization) Vaccines and vaccine compositions, and methods for the manufacture thereof
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
WO2012089231A1 (en) * 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
TWI620816B (en) 2011-03-23 2018-04-11 苜蓿股份有限公司 Method of recovering plant-derived proteins
AR088028A1 (en) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed PROTEINS H5, FROM H5N1 FOR MEDICINAL USE
WO2013043729A1 (en) 2011-09-20 2013-03-28 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
WO2013044203A2 (en) * 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
CA3207612A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US9234008B2 (en) * 2012-02-07 2016-01-12 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for H3N2, H2N2, and B influenza viruses
GB201203534D0 (en) * 2012-02-29 2012-04-11 Vela Operations Pte Ltd Real-time PCR detection of seasonal influenza H1, H3 and B subtypes
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
CN104780936A (en) * 2012-11-16 2015-07-15 米迪缪尼有限公司 Swine influenza hemagglutinin and neuraminidase variants
CN108641002A (en) 2012-12-18 2018-10-12 西奈山伊坎医学院 Influenza virus vaccine and application thereof
AU2014204826A1 (en) * 2013-01-10 2015-07-09 Seqirus UK Limited Influenza virus immunogenic compositions and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
AU2014276418A1 (en) * 2013-06-06 2016-01-21 Novartis Ag Influenza virus reassortment
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
BR112016007868A2 (en) 2013-10-11 2017-12-05 Us Health epstein-barr virus vaccines
CA2936350C (en) 2014-01-10 2023-01-31 Medicago Inc. Cpmv enhancer elements
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
WO2016109792A2 (en) 2014-12-31 2016-07-07 The Usa, As Represented By The Secretary, Detp. Of Health And Human Services Novel multivalent nanoparticle-based vaccines
AU2016209032A1 (en) 2015-01-23 2017-08-10 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2017143236A1 (en) 2016-02-19 2017-08-24 Yoshihiro Kawaoka Improved influenza b virus replication for vaccine development
SG11201810758WA (en) 2016-06-03 2018-12-28 Sanofi Pasteur Inc Modification of engineered influenza hemagglutinin polypeptides
JP7237344B2 (en) * 2016-06-15 2023-03-13 アイカーン スクール オブ メディシン アット マウント サイナイ Influenza virus hemagglutinin protein and uses thereof
CA3035443A1 (en) 2016-09-02 2018-03-08 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992522A (en) 1973-01-24 1976-11-16 The United States Of America As Represented By The Department Of Health, Education And Welfare Temperature-sensitive recombinant mutant viruses and a process for producing same
US4071618A (en) 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
JPS57136528A (en) 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
CH652145A5 (en) 1982-01-22 1985-10-31 Sandoz Ag METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
EP0310361A3 (en) * 1987-09-30 1989-05-24 Beckman Instruments, Inc. Tridentate conjugate and method of use thereof
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
EP1473361A3 (en) 1992-04-14 2004-11-17 The Mount Sinai School Of Medicine, Of The City University Of New York Genetically engineered attenuated viruses
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Attenuated respiratory syncytial virus vaccine compositions
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
ATE257175T1 (en) 1994-07-18 2004-01-15 Conzelmann Karl Klaus Prof Dr RECOMBINANT INFECTIOUS NON-SEGMENTED, NEGATIVE STRAND RNA VIRUS
US5716821A (en) 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
US5789229A (en) 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5690937A (en) 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
DE69510207T3 (en) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Process for producing infectious minus-stranded RNA viruses
JPH11512609A (en) 1995-09-27 1999-11-02 アメリカ合衆国 Production of infectious respiratory syncytial virus from cloned nucleotide sequence
KR100552387B1 (en) 1995-10-31 2006-04-21 가부시끼가이샤 디나벡 겡뀨쇼 (-)-Strand RNA Virus Vector Having Autonomously Replicating Activity
CN1143892C (en) 1995-11-01 2004-03-31 株式会社载体研究所 Recombinant sendal virus
US6090391A (en) 1996-02-23 2000-07-18 Aviron Recombinant tryptophan mutants of influenza
KR100658491B1 (en) 1996-07-15 2006-12-18 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
CA2265554A1 (en) 1996-09-27 1998-04-02 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
CN1250725C (en) 1997-05-23 2006-04-12 美国政府健康及人类服务部 Prodn of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
DE69837764T2 (en) 1997-07-11 2008-01-31 Yale University, New Haven RHABDOVIRUS WITH GENUINE CHANGED CASE
JP2001517448A (en) 1997-09-19 2001-10-09 アメリカン・サイアナミド・カンパニー Attenuated respiratory syncytial virus
US6033866A (en) * 1997-12-08 2000-03-07 Biomedix, Inc. Highly sensitive amperometric bi-mediator-based glucose biosensor
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
EP1035209A1 (en) 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Stable recombinant influenza viruses free of helper viruses
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
DK2345716T3 (en) 1999-04-06 2015-02-09 Wisconsin Alumni Res Found RECOMBINANT INFLUENZAVIRA FOR VACCINES AND GENTHERAPY
RU2280690C2 (en) 2000-03-02 2006-07-27 Полимун Сайнтифик Иммунбиологише Форшунг Гмбх Recombinant influenza virus a
ATE420189T1 (en) 2000-04-28 2009-01-15 St Jude Childrens Res Hospital DNA TRANSFECTION SYSTEM FOR GENERATING INFECTIOUS NEGATIVE STRAND RNA VIRUS
CN1582333B (en) 2000-09-25 2010-06-16 波利门科学生物免疫研究有限公司 Live vaccine and method of manufacture
EP1361890B1 (en) * 2001-02-23 2011-03-30 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
USPP15035P3 (en) * 2001-06-27 2004-07-27 Marko Zaninovich, Inc. Grapevine ‘12-76-71’
CN103540568A (en) 2002-04-26 2014-01-29 米迪缪尼有限公司 Multi plasmid system for the production of influenza virus
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
CA2807534A1 (en) * 2003-02-25 2005-02-17 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
CN100482788C (en) 2003-04-10 2009-04-29 中国疾病预防控制中心病毒病预防控制所 High-yield recombinant influenza B virus strain and its application
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US7037707B2 (en) 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
JP4980896B2 (en) 2004-05-25 2012-07-18 メディミューン，エルエルシー Influenza hemagglutinin and neuraminidase variants
US8043813B2 (en) 2004-11-01 2011-10-25 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Method of detecting H5 or H7 avian influenza virus
CA2586690A1 (en) 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics, Inc. Influenza vaccination
ES2526170T3 (en) 2004-12-23 2015-01-07 Medimmune, Llc MDCK non-tumorigenic cell line to spread virus
EP2441471B1 (en) 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
WO2007103322A2 (en) 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
CA2676028A1 (en) 2007-01-18 2008-11-27 Samuel Bogoch Methods of determining lethality of pathogens and malignancies involving replikin peak genes
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
WO2010006144A2 (en) 2008-07-11 2010-01-14 Medlmmune, Llc. Influenza hemagglutinin and neuraminidase variants

Also Published As

Publication number Publication date
CA2816222A1 (en) 2005-03-03
US20050042229A1 (en) 2005-02-24
US7459162B2 (en) 2008-12-02
US8404248B2 (en) 2013-03-26
EP1633312A2 (en) 2006-03-15
CA2529647A1 (en) 2005-03-03
EP1633312A4 (en) 2012-09-26
US20110002960A1 (en) 2011-01-06
US20120301503A1 (en) 2012-11-29
US8877210B2 (en) 2014-11-04
US20090175908A1 (en) 2009-07-09
US20130243816A1 (en) 2013-09-19
US7566458B2 (en) 2009-07-28
US20060252132A1 (en) 2006-11-09
WO2005018539A2 (en) 2005-03-03
US8685410B2 (en) 2014-04-01
EP2581093B1 (en) 2015-03-18
EP2581093A1 (en) 2013-04-17
CA2529647C (en) 2013-08-13
US20120034265A1 (en) 2012-02-09
US8048430B2 (en) 2011-11-01
US20140242102A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
WO2005018539A8 (en) Influenza hemagglutinin and neuraminidase variants
HK1179648A1 (en) Influenza hemagglutinin and neuraminidase variants
EP2056872A4 (en) Influenza hemagglutinin and neuraminidase variants
EP1603590A4 (en) Influenza virus vaccine
WO2006098901A3 (en) Influenza hemagglutinin and neuraminidase variants
PL2478916T3 (en) Influenza vaccines containing hemagglutinin and matrix proteins
AU2003214886A1 (en) Spray can targeting and positioning system
HK1067891A1 (en) Influenza vaccine composition
EP1708748A4 (en) Influenza immunogen and vaccine
AU2003251088A1 (en) Nasal devices
AU2003222621A1 (en) Nasal devices
AU2003221497A1 (en) Pharmaceutical microparticles
EP1603619A4 (en) Nasal assembly
EP1622573A4 (en) Molecules enhancing dermal delivery of influenza vaccines
EP1906998A4 (en) Peptide-based influenza vaccine formulation
SE0202752L (en) Plasma spray device
AU2003238868A8 (en) Software atomization
AU2001238401A1 (en) Cold-adapted equine influenza viruses
DE60234477D1 (en) ACCUMULATORS-liquid spray
AU3840101A (en) Cold-adapted equine influenza viruses
AU2003285320A1 (en) Vaccine
AU2003292859A1 (en) Feng-you-jing spray
GB2402394B (en) Rubber-acrylic adhesive formulation
AU2003272974A1 (en) Anti-influenza virus agent
GB0201520D0 (en) Pharmaceutical uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2529647

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004785947

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2004785947

Country of ref document: EP